Table 3.
Values of V5, V20 and mean lung dose (MLD) in total lung and top 20%, 30% and 40% functional lung regions for all the investigated anatomic treatment plans
|
Patient |
Anatomic |
Functional lung region |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Total lung |
20% |
30% |
40% |
||||||||
| V5 (%) | V20 (%) | MLD (Gy) | V5 (%) | V20 (%) | MLD (Gy) | V5 (%) | V20 (%) | MLD (Gy) | V5 (%) | V20 (%) | MLD (Gy) | |
| 1 |
11.6 |
7.1 |
3.8 |
5.1 |
2.6 |
1.6 |
7.9 |
4.4 |
2.6 |
9.4 |
5.6 |
3.2 |
| 2 |
26.74 |
16.9 |
9.3 |
17.9 |
9.7 |
5.5 |
21 |
11.8 |
6.7 |
22.9 |
13.4 |
7.6 |
| 3 |
50.6 |
18.6 |
11.07 |
40.6 |
15.8 |
9.4 |
42.6 |
17 |
9.9 |
42.6 |
17.4 |
10 |
| 4 |
25.2 |
17.8 |
9.4 |
16.1 |
10.6 |
5.8 |
19.6 |
13.3 |
7.2 |
22.3 |
15.5 |
8.3 |
| 5 |
47.3 |
16.8 |
10.3 |
29.2 |
8.3 |
6 |
36.2 |
12 |
7.9 |
40.1 |
13.9 |
8.8 |
| 6 |
41.9 |
16.2 |
8.6 |
27 |
8.5 |
5.4 |
33.9 |
11.9 |
6.8 |
38.1 |
14.2 |
7.7 |
| AVG ± STD |
33.9 ± 15.1 |
15.6 ± 4.2 |
8.7 ± 2.6 |
22.7 ± 12.3 |
9.3 ± 4.3 |
5.6 ± 2.5 |
26.9 ± 12.9 |
11.7 ± 4.1 |
6.9 ± 2.4 |
29.2 ± 13.1 |
13.3 ± 4.1 |
7.6 ± 2.3 |
| 7 |
66.4 |
30.3 |
16.7 |
67.4 |
31.2 |
17.1 |
67.1 |
30 |
16.8 |
67.1 |
30 |
16.7 |
| 8 |
34.4 |
18.3 |
8.7 |
38.3 |
21.8 |
9.9 |
36.7 |
20.4 |
9.3 |
36.4 |
20.2 |
9.3 |
| 9 |
57.7 |
25.7 |
13.2 |
45 |
19.3 |
10.2 |
51.5 |
23 |
11.9 |
55.5 |
25.1 |
12.9 |
| 10 |
62.1 |
27.2 |
14.4 |
64.1 |
26 |
14.1 |
62.3 |
25.3 |
13.7 |
61.1 |
25 |
13.6 |
| 11 |
46.7 |
29.5 |
17.8 |
31.4 |
13.3 |
9.2 |
37.4 |
18.5 |
12.1 |
40.9 |
22.1 |
14 |
| AVG ± STD | 53.5 ± 12.9 | 26.2 ± 4.8 | 14.2 ± 3.6 | 49.2 ± 15.9 | 22.3 ± 6.8 | 12.1 ± 3.4 | 51.0 ± 13.9 | 23.4 ± 4.5 | 12.7 ± 2.7 | 52.2 ± 13.1 | 24.5 ± 3.7 | 13.2 ± 2.5 |